Close Menu

NEW YORK (360Dx) – Multiple new technologies have emerged in recent years for isolating circulating tumor cells, some of which are now making more definitive moves towards the clinic.

Angle, a UK-based firm with a label-free system called Parsortix, announced last week, for example, that it has enrolled the first patient in its ANG-002 breast cancer clinical study, which is intended to support submission of Parsortix to the US Food and Drug Administration.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.